VUNO announced on the 4th that it has completed the transfer of its VUNO Med-BoneAge assets to Medihub Co., Ltd. for 2.7 billion won.

Circumstances of the Transaction's Conclusion

This transaction follows VUNO's decision on a major asset transfer, disclosed on September 10 of last year. At that time, VUNO signed a "Contract for Asset Transfer and Patent Assignment" with Medihub.

The transaction was delayed beyond its originally scheduled closing date. VUNO explained that negotiations over the relevant procedures continued while it carried out the process of transferring the assets in question. Accordingly, the two parties signed an agreement on the related matters on this day.

VUNO stated that the transaction was concluded normally, with the full transaction price, including the balance, having been paid.

Financial Effects

According to the summary financial information before and after the asset transfer presented in the disclosure, total assets will increase by 2.7 billion won, from 49.393762 billion won to 52.093762 billion won. Total capital is also presented as rising by 2.7 billion won, from 34.297197572 billion won to 36.997197572 billion won.

However, among the summary financial information, the pre-transfer figures were prepared based on the separate financial statements as of the end of the third quarter of 2025. The post-transfer financial information simply reflects the addition and subtraction of amounts related to this transaction, and actual financial figures may differ depending on the results of audits or reviews by external auditors.